Journal Highlights
Dupilumab: a revolutionary emerging drug in atopic dermatitis and its possible role in pemphigus
Soheil Tavakolpour,
Corresponding Author
Soheil Tavakolpour
Islamic Azad University, Science and Research Branch, Poonak, Tehran, Iran
Address correspondence and reprint requests to: Soheil Tavakolpour, MS, Islamic Azad University, Science and Research Branch, Poonak, Tehran, Iran, or email:
[email protected].
Search for more papers by this author
Soheil Tavakolpour,
Corresponding Author
Soheil Tavakolpour
Islamic Azad University, Science and Research Branch, Poonak, Tehran, Iran
Address correspondence and reprint requests to: Soheil Tavakolpour, MS, Islamic Azad University, Science and Research Branch, Poonak, Tehran, Iran, or email:
[email protected].
Search for more papers by this author
First published: 22 January 2016
No abstract is available for this article.
References
- 1
Beck LA,
Thaçi D,
Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014; 371: 130–139.
- 2
Hamilton JD,
Suárez-Fariñas M,
Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014; 134: 1293–1300.
- 3
Thaçi D,
Simpson EL,
Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. The Lancet 2015.
- 4
Tavakolpour S,
Tavakolpour V. Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine 2016; 77: 189–195.
